Connect with us

Biotech

BioNTech: First data for the COVID-19 vaccine to be soon presented

BioNTech CEO Sierk Pötting expects to be able to present the first data from the ongoing study on the efficacy of BNT162 at the end of October or beginning of November. BioNTech and marketing partner Pfizer are currently building up production capacities for BNT162. BioNTech’s shares rose 0.46 percent to $94.35 on a closing price basis on the NASDAQ yesterday, October 20th.

Suzanne Mitchell

Published

on

BioNTech CEO Sierk Pötting believes that the company is on track with the development of the SARS-CoV-2 vaccine candidate BNT162. The safety profile looks good, said Pötting at the Finance Day 2020 of GoingPublic and Platform Life Sciences. 

So far, there have been no reportable security incidents. However, the ongoing clinical study is not yet at an end, according to the CFO & COO of the Mainz-based biotech company, which is now listed on the stock exchange in the double-digit billions. BioNTech‘s shares are listed on the primary stock exchange NASDAQ, among others, but can also be traded on German stock markets.

If you want to find more details about BioNTech and when its vaccine against COVID-19 will be released on the market, download for free the Born2Invest mobile app. Our companion app brings you the latest breakthroughs in the biotech sector and the most important financial headlines in the world, so you can stay informed.

When will the first data about the COVID-19 vaccine be presented

Pötting expects to be able to present the first data from the ongoing study on the efficacy of BNT162 at the end of October or beginning of November. In previous studies, the vaccine has already provided promising immunity data and, together with Moderna’s vaccine candidate, is considered to be the most promising and advanced vaccine project against the pathogen of the corona pandemic, the SARS-CoV-2 virus.

BioNTech and marketing partner Pfizer are currently building up production capacities for BNT162. Pfizer CEO Albert Bourla announced on Friday that the vaccine could be submitted for approval in the USA in the third week of November.

SEE ALSO  Why you should make catch-up contributions to your retirement plan

The prerequisite is that both the clinical trial and the production facilities meet the requirements for an application for approval. “First, the vaccine must be proven to be effective, i.e. it can help prevent COVID-19 disease in at least the majority of vaccinated patients. Second, and equally important, the vaccine must have been proven safe, with robust safety data from thousands of patients. And finally, we must prove that the vaccine can be consistently produced to the highest quality standards,” the Pfizer CEO said in the open letter on Friday – we reported.

BioNTech stock: The fronts are hardening

BioNTech’s shares rose 0.46 percent to $94.35 on a closing price basis on the NASDAQ yesterday, October 20th. However, that sounds more boring than the charts ultimately showed for the biotech stock. Share prices for the bearer of hope in the fight against the Corona pandemic ranged between $91.61 and $96.12. That means that the share price of the Mainz-based company was able to successfully defend itself against new sell signals on the charts, which could exert pressure after the recent rally. 

At the same time, however, there was no breakthrough upwards towards an all-time high of $105. The technical fronts are thus hardening, and the signal marks for the BioNTech share have not changed. The central resistance level on the charts is currently $96.09/$97.82. Although this came into view last week, “real” tests were only carried out on Monday with a daily high at $97.29 and yesterday, October 20th. Both tests had no success.

SEE ALSO  Home exchanges: A trend in traveling and lodging

__

(Featured image by coyot via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in 4investors, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.

Suzanne Mitchell juggles the busy life of a full-time mom and entrepreneur while also being a writer-at-large for several business publications. Her work mostly covers the financial sector, including traditional and alternative investing. She shares reports and analyses on the real estate, fintech and cryptocurrency markets. She also likes to write about the health and biotech industry, in particular its intersection with clean water and cannabis. It is one of her goals to always share things of interest to women who want to make their mark in the world.